M&As this week: Strides Pharma Science, Lambda Therapeutic Research, NextPharma
Strides Pharma Science’s step-down subsidiary Strides Pharma has made an arrangement to acquire Vensun Pharmaceuticals for $18m.
Strides Pharma Science’s step-down subsidiary Strides Pharma has made an arrangement to acquire Vensun Pharmaceuticals for $18m.
Takeda Pharmaceutical has completed an acquisition of Shire for $62bn.
Sanofi and Regeneron Pharmaceuticals have entered a revised agreement for the development of novel cancer treatments.
EQT has agreed to increase its acquisition offer for Karo Pharma to Skr6.15bn ($694m) through the EQT VIII fund.
Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m.
GlaxoSmithKline (GSK) and Pfizer have agreed to combine their consumer healthcare businesses with combined annual sales of £9.8bn ($12.7bn)…
Vect-Horus has signed a research agreement with Janssen Pharmaceuticals for the development of neurodegenerative disease treatments.
GlaxoSmithKline (GSK) has agreed to acquire US-based cancer treatment developer Tesaro for $5.1bn.
Boehringer Ingelheim and Domain Therapeutics have entered a deal to collaborate on a drug discovery project.
Thank you for subscribing to Pharmaceutical Technology